Novo Nordisk has ended its short-lived partnership with Hims & Hers Health, saying the telehealth company continued to sell unapproved versions of its weight loss drug, Wegovy. The partnership, launched just over a month ago, gave Hims & Hers direct access to Wegovy through Novo’s online pharmacy.

The decision comes after the FDA declared that Wegovy is no longer in short supply. That change made it illegal to keep selling compounded versions—custom-mixed alternatives not approved by the FDA. Novo says Hims & Hers ignored that and used misleading marketing to promote knock-off versions made with ingredients from overseas suppliers that haven’t been inspected by the FDA.

Hims & Hers pushed back, saying Novo tried to pressure them into promoting Wegovy over other options and that they’ll continue offering a range of treatments. Following the news, Hims & Hers' stock dropped nearly 30%.

Novo says it will keep working with telehealth companies that follow safety rules to ensure patients get real, FDA-approved medication.

For more information, please visit Fierce Healthcare.